Edition:
United States

Ionis Pharmaceuticals Inc (IONS.OQ)

IONS.OQ on NASDAQ Stock Exchange Global Select Market

44.64USD
18 May 2018
Change (% chg)

$0.81 (+1.85%)
Prev Close
$43.83
Open
$43.76
Day's High
$44.71
Day's Low
$43.59
Volume
348,195
Avg. Vol
389,372
52-wk High
$65.51
52-wk Low
$39.08

Chart for

About

Ionis Pharmaceuticals, Inc. is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company's segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment,... (more)

Overall

Beta: 2.46
Market Cap(Mil.): $5,501.56
Shares Outstanding(Mil.): 125.52
Dividend: --
Yield (%): --

Financials

  IONS.OQ Industry Sector
P/E (TTM): 58.89 223.30 32.53
EPS (TTM): 0.76 -- --
ROI: 7.91 -8.07 12.63
ROE: 38.34 -10.87 14.50

BRIEF-Ionis Reports Q1 Total Revenue Of $144 Mln Vs $116 Mln

* FOR Q1 OF 2018, BASIC AND DILUTED NET LOSS PER SHARE WERE $0.01 Source text for Eikon: Further company coverage:

May 04 2018

Biogen boosts investment in neurology with $1 billion Ionis deal

Biogen Inc struck a $1 billion neurology drug development deal with Ionis Pharmaceuticals on Friday, expanding a partnership that developed the company's potential blockbuster drug for spinal muscular atrophy.

Apr 20 2018

BRIEF-Biogen And Ionis Expand Strategic Collaboration To Develop Drug Candidates For A Broad Range Of Neurological Diseases

* BIOGEN AND IONIS EXPAND STRATEGIC COLLABORATION TO DEVELOP DRUG CANDIDATES FOR A BROAD RANGE OF NEUROLOGICAL DISEASES

Apr 20 2018

UPDATE 2-Biogen boosts investment in neurology with $1 bln Ionis deal

* Comprises equity investment in Ionis plus upfront payment (Adds background, share movement)

Apr 20 2018

Biogen to pay $1 billion to Ionis in new partnership

April 20 Drugmaker Biogen Inc said on Friday it would pay Ionis Pharmaceuticals Inc $1 billion in cash as part of a new ten-year agreement to develop medicines for a broad range of neurological diseases including dementia.

Apr 20 2018

Ionis may get up to $300 million in licensing deal with AstraZeneca

Ionis Pharmaceuticals Inc said on Monday a licensing deal for its fatty liver disease treatment with AstraZeneca Plc could fetch up to $300 million in milestone payments.

Apr 09 2018

UPDATE 1-Ionis may get up to $300 mln in licensing deal with AstraZeneca

April 9 Ionis Pharmaceuticals Inc said on Monday a licensing deal for its fatty liver disease treatment with AstraZeneca Plc could fetch up to $300 million in milestone payments.

Apr 09 2018

Ionis to get up to $300 mln from licensing deal with AstraZeneca

April 9 Ionis Pharmaceuticals said on Monday it signed a licensing deal for its fatty liver disease treatment with AstraZeneca Plc that could land the company up to $300 million in milestone payments and royalties.

Apr 09 2018

BRIEF-Ionis And AstraZeneca Advance New Drug For NASH

* IONIS PHARMACEUTICALS INC - EARNS $30 MLN LICENSE FEE FOR IONIS-AZ6-2.5-L RX

Apr 09 2018

Pfizer's rare heart disease drug succeeds in late-stage study

Pfizer Inc's experimental drug to treat a rare and fatal disease linked to heart failure reduced deaths and need for hospitalizations in a late-stage study.

Mar 29 2018

Competitors

Earnings vs. Estimates